Some premenopausal breast cancer patients use phytoestrogen-rich soy and flaxseed to alleviate side effects induced by drugs such as tamoxifen (TAM). Lignan-rich flaxseed protects against breast cancer and increases the effectiveness of TAM. This study determined the interactive effects of lignan-rich sesame seed (SS) and TAM on estrogen-responsive MCF-7 breast tumor growth and bone health in ovariectomized athymic mice under premenopausal-simulated conditions. Ovariectomized mice with an estrogen implant and established MCF-7 tumors were treated for 8 weeks as follows: (i) positive control fed basal diet (BD), (ii) SS group fed BD supplemented with 10% ground SS, (iii) TAM group with TAM implant fed BD, (iv) SS + TAM group with TAM implant fed BD supplemented with 10% SS, and (v) negative control fed BD with no estrogen implant. Palpable tumor data, adjusted for body weight, showed that SS does not inhibit MCF-7 tumor growth and tends to negate the tumor inhibitory effect of TAM by increasing cell proliferation and reducing apoptosis. SS alone and combined with TAM enhanced femur biomechanical strength but caused no differences in bone mineral content or bone mineral density in either the femur or lumbar vertebrae. SS is not protective and interacts adversely with TAM in MCF-7 breast tumors but induces beneficial effects on bone both alone and when combined with TAM.
Get full access to this article
View all access options for this article.
References
1.
Adlercreutz H, Mazur W. Phyto-estrogens and Western diseases. Ann Med29:95–120, 1997.
2.
Dai Q, Franke A, Jin F, Shu X, Hebert J, Custer L, Cheng J, Gao Y, Zheng W. Urinary excretion of phytoestrogens and risk of breast cancer among Chinese women in Shanghai. Cancer Epidemiol Biomarkers Prev11:815–821, 2002.
3.
Linseisen J, Piller R, Hermann S, Chang-Claude J. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study. Int J Cancer110:284–290, 2004.
4.
McCann S, Muti P, Vitp D, Edge S, Trefisan M, Freudenheim J. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer. Int J Cancer111:440–443, 2004.
5.
Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, Adlercreutz H. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev10:339–344, 2001.
6.
Thompson LU, Boucher BA, Liu Z, Cotterchio M, Kreiger N. Phytoestrogen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer54:184–201, 2006.
7.
Thompson LU, Robb P, Serraino M, Cheung F. Mammalian lignan production from various foods. Nutr Cancer16:43–52, 1991.
8.
Coulman KD, Liu Z, Hum WQ, Michaelides J, Thompson LU. Whole sesame seed is a rich source of mammalian lignan precursors as whole flaxseed. Nutr Cancer52:156–165, 2005.
9.
Liu Z, Saarinen NM, Thompson LU. Sesamin is one of the major precursors of mammalian lignans in sesame seed (Sesamum indicum) as observed in vitro and in rats. J Nutr136:906–912, 2006.
10.
Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. Br J Nutr89(Suppl 1):S45–S58, 2003.
11.
Power KA, Thompson LU. Flaxseed and lignans: Effects on breast cancer. In: Awad AB, Bradford PG, Eds. Nutrition and Cancer Prevention. Boca Raton, FL: Taylor & Francis Group, pp385, 2006.
12.
Phipps WR, Martini MC, Lampe JW, Slavin JL, Kurzer MS. Effect of flax seed ingestion on the menstrual cycle. J Clin Endocrinol Metab77: 1215–1219, 1993.
13.
Wilcox G, Wahglvist ML, Burger HG, Medley G. Oestrogenic effects of plant foods in postmenopausal women. Br Med J301:905–906, 1990.
14.
Chen J, Hui E, Ip T, Thompson LU. Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen dependent human breast cancer (MCF-7) in nude mice. Clin Cancer Res10:7703–7711, 2004.
15.
Chen J, Thompson LU. Lignans and tamoxifen, alone or in combination, reduce human breast cancer cell adhesion, invasion and migration in vitro. Breast Cancer Res Treat80:163–170, 2003.
16.
Chen J, Wang L, Thompson LU. Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett234:168–175, 2006.
17.
Dabrosin C, Chen J, Wang L, Thompson LU. Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett185:31–37, 2002.
18.
Power KA, Saarinen NM, Chen JM, Thompson LU. Mammalian lignans enterolactone and enterodiol, alone and in combination with the isoflavone genistein, do not promote the growth of MCF-7 xenografts in ovariectomized athymic nude mice. Int J Cancer118:1316–1320, 2006.
19.
Bergman Jungeström M, Thompson LU, Dabrosin C. Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis and secretion of VEGF in human breast cancer xenografts in vivo. Clin Cancer Res13: 1061–1067, 2007.
20.
Power KA, Ward WE, Chen JM, Saarinen NM, Thompson LU. Genistein alone and in combination with the mammalian lignans enterolactone and enterodiol induce estrogenic effects on bone and uterus in a postmenopausal breast cancer mouse model. Bone39:117–124, 2006.
21.
Duffy C, Cyr M. Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health12:617–631, 2003.
22.
Penalvo JL, Heinonen SM, Aura AM, Adlercreutz H. Dietary sesamin is converted to enterolactone in humans. J Nutr135:1056–1062, 2005.
23.
Olfert ED, Cross BM, McWilliam AA, Eds. Guide to the Care and Use of Experimental Animals, (2nd ed.). Ottawa: Canadian Council on Animal Care, Vol 1, 1993.
24.
Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformation of the AIN-76A rodent diet. J Nutr123:1939–1951, 1993.
25.
Fonseca D, Ward WE. Daidzein together with high calcium preserve bone mass and biomechanical strength at multiple sites in ovariectomized mice. Bone35:489–497, 2004.
26.
Asarian L, Geary N. Modulation of appetite by gonadal steroid hormones. Philos Trans R Soc Lond B Biol Sci361:1251–1263, 2006.
27.
Geary N, Asarian L, Korach KS, Pfaff DW, Ogawa S. Deficits in estrogen-dependent control of feeding, weight gain, and cholecystokinin satiation in ER-alpha null mice. Endocrinology142:4751–4757, 2001.
28.
Jordan VC, Phelps E, Lindgren JU. Effects of anti-estrogens on bone in castrated and intake female rats. Breast Cancer Res Treat10:31–35, 1987.
29.
Wallen JW, Belanger MP, Wittnich C. Sex hormones and the selective estrogen receptor modulator tamoxifen modulate weekly body weights and food intakes in adolescent and adult rats. J Nutr131:2351–2357, 2001.
30.
Hirose N, Doi F, Ueki T, Akazawa K, Chijiiwa K, Sugano M, Akimoto K, Shimizu S, Yamada H. Suppressive effect of sesamin against 7, 12-dimethylbenz[a]-anthracene induced rat mammary carcinogenesis. Anticancer Res12:1259–1265, 1992.
31.
Sheng H, Hirose Y, Hata K, Zheng O, Kuno T, Asano N, Yamada Y, Hara A, Osawa T, Mori H. Modifying effect of dietary sesaminol glucosides on the formation of azoxymethane-induced premalignant lesions of rat colon. Cancer Lett246:63–68, 2007.
32.
Sirato-Yasumoto S, Katsuta M, Okuyama Y, Takahashi Y, Ide T. Effect of sesame seed rich in sesamin and sesamolin on fatty acid oxidation in rat liver. J Agric Food Chem49:2647–2651, 2001.
33.
Wu WH, Kang YP, Wang NH, Jou HJ, Wang TA. Sesame ingestion affects sex hormones, antioxidant status, and blood lipids in postmenopausal women. J Nutr136:1270–1275, 2006.
34.
Phillips KM, Ruggio DM, Ashraf-Khorassani M. Phytosterol composition of nuts and seeds commonly consumed in the United States. J Agric Food Chem53:9436–9445, 2005.
Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell5:207–213, 2004.
37.
Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res48:5183–5187, 1988.
38.
MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev50:151–196, 1998.
39.
Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet365: 1687–1717, 2005.
40.
Osborne KC, Hobbs K, Clark GM. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res45:584–590, 1985.
41.
Lewis JS, Jordan VC. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res591: 247–263, 2005.
42.
Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis6:469–477, 2001.
43.
Nakano D, Kwak CJ, Fujii K, Ikemura K, Satake A, Ohkita M, Takaoka M, Ono Y, Nakai M, Tomimori N, Kiso Y, Matsumura Y. Sesamin metabolites induce an endothelial nitric oxide-dependent vasorelaxation through their antioxidative property-independent mechanisms: possible involvement of the metabolites in the antihypertensive effect of sesamin. J Pharmacol Exp Ther318:328–335, 2006.
44.
Khan A. Management of low bone mineral density in premenopausal women. J Obstet Gynaecol Can27:345–349, 2005.
45.
Mackey JR, Joy AA. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer114:1010–1015, 2005.
46.
Vehmanen L, Elomaa I, Blomqvist C, Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol24:675–680, 2006.
47.
Lee SK, Kadono Y, Okada F, Jacquin C. Koczon-Jaremko B, Gronowicz G, Adams DJ, Aquila HL, Choi Y, Lorenzo JA. T lymphocyte-deficient mice lose trabecular bone mass with ovariectomy. J Bone Miner Res21:1704–1712, 2006.
48.
Reed CA, Berndtson AK, Nephew KP. Dose-dependent effects of 4-hydroxytamoxifen, the active metabolite of tamoxifen, on estrogen receptor-alpha expression in the rat uterus. Anticancer Drugs16:559–567, 2005.
